Harold Edward Zylicz Ii, PA | |
8585 Picardy Ave Ste 210, Baton Rouge, LA 70809-3749 | |
(225) 819-1181 | |
(225) 246-8333 |
Full Name | Harold Edward Zylicz Ii |
---|---|
Gender | Male |
Speciality | Physician Assistant |
Location | 8585 Picardy Ave Ste 210, Baton Rouge, Louisiana |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1366096950 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | 320117 (Louisiana) | Secondary |
363A00000X | Physician Assistant | 320117 (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Harold Edward Zylicz Ii, PA 8585 Picardy Ave Ste 210, Baton Rouge, LA 70809-3749 Ph: (225) 819-1181 | Harold Edward Zylicz Ii, PA 8585 Picardy Ave Ste 210, Baton Rouge, LA 70809-3749 Ph: (225) 819-1181 |
News Archive
Most healthy cells rely on a complicated process to produce the fuel ATP. Knowing how ATP is produced by the cell's energy storehouse - the mitochondria - is important for understanding a cell's normal state, as well as what happens when things go wrong, for example in cancer, cardiovascular disease, neurodegeneration, and many rare disorders of the mitochondria.
Potatoes are often equated with refined grains due to their carbohydrate content. Yet, potatoes contain fiber, resistant starch, and key micronutrients that Americans need more of in their diet.
Neuro-Biotech Corporation introduces a Neuro-biomarker which is linked to a series of Neuro-Bio tests. This will permit to understand the science behind them and how they each will contribute to a progressive clinical investigation involving the input and output of the brain.
QLT Inc. today announced final 24-month results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with exudative (wet) age-related macular degeneration. The purpose of the study was to determine if Visudyne® combined with Lucentis® reduced retreatment rates compared with Lucentis monotherapy, while maintaining similar vision outcomes and an acceptable safety profile.
› Verified 5 days ago